Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Roche and Ionis report a 43.1% Phase 3 proteinuria reduction with sefaxersen. Two-year kidney function results remain the next major test.
Pharma & Biotech
Pharma & Biotech
Is Novartis Pharma AG positioned to convert accelerated approval for Vanrafia in 2026?
Novartis reports Phase III ALIGN data for Vanrafia in IgA nephropathy. Discover what this means for full approval in 2026.
Pharma & Biotech
Oral complement therapy for myasthenia gravis? Novartis’ iptacopan enters the neurology arena
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.